Skip to content

Metabolomics in Occupational Asthma

Pilot Study of Metabolomics in Occupational Asthma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04301674
Enrollment
80
Registered
2020-03-10
Start date
2021-10-15
Completion date
2023-06-01
Last updated
2022-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Occupational

Brief summary

The project aims to increase the diagnostic accuracy in occupational asthma (OA), with emphasis on Irritant Induced Asthma (IIA). Currently, most patients are evaluated in occupational medicine by comparing the exposure and symptom characteristics with epidemiological data. Biological markers may be present in AA, but presently not in IIA. The majority of cases evaluated are considered as possible IIA, i.e. low-dose multiple exposures. VOC features will be analyzed with the Breath Biopsy® and TD-GS-MS (Owlstone Medical Ltd, UK).

Interventions

ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)

Sponsors

Owlstone Ltd
CollaboratorINDUSTRY
Oslo University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* capable of informed consent. * asthma diagnosis established by lung specialist or healthy control.

Exclusion criteria

* skin allergy towards plastics or rubber. * immunocompromised by oral medication. * contagious respiratory disease. * biopsy of lung parenchyma within the last 36 hours.

Design outcomes

Primary

MeasureTime frameDescription
Discovery of VOC Biomarkers in AsthmaBaselineTo evaluate the sensitivity, specificity, positive and negative predictive value of VOC biomarkers in exhaled breath samples to identify asthma.
Discovery of VOC Biomarkers in Occupational Irritant AsthmaBaselineTo evaluate the sensitivity, specificity, positive and negative predictive value of VOC biomarkers in exhaled breath samples to identify irritant asthma after occupational exposures.

Countries

Norway

Contacts

Primary ContactBato Hammarström, MD/PhD
bato.hammarstrom@ous-hf.no+47 230 16667
Backup ContactTonje Trulssen Hildre, M.Sc.
tohild@ous-hf.no

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026